Background: Procalcitonin (PCT) was first described in the early 1960s as a precursor of calcitonin that is synthesized mainly in the thyroid and lung tissues. It is an immediate biosynthetic product in response to bacterial toxins and the pro-inflammatory cytokines, which in turn makes it a distinctive biomarker for bacterial infections. The present analysis deals with the study on the biochemical characteristics, production pathways, and clinical uses of PCT as a diagnostic tool. Methods: During March and June 2024, a cross-sectional study was performed, among 357 patients with the proper characteristics who were admitted to the hospital and got their PCT levels, there were those who had respiratory, cardiac, gastrointestinal, and systemic infections. The exclusion criteria were the hospital stay of less than 24 h and a few noninfectious diseases. Results: The higher PCT levels (> 0.5 ng/mL) reliably informed about the presence of bacterial infections like pneumonia, endocarditis, urinary tract infections, and sepsis. PCT levels demonstrated trivial increase in viral as well as fungal infections. The study ratified the significant relationship between PCT levels and the severity of bacterial infections, thus backing its usefulness in the diagnosis and treatment control. Conclusion: Procalcitonin is increasingly emerging as a trustworthy biomarker for bacterial infections, thus helping in the early diagnosis, guiding targeted antibiotic therapy, and reducing inappropriate antibiotic use. Its high specificity for bacterial etiology has largely contributed to the success and potency of antibiotic stewardship programs.
29 May 2025 in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
Background: This study aimed to assess the knowledge, perception, and awareness of polycystic ovarian syndrome (PCOS) symptoms and complications among college women’s in Chennai, India, to identify gaps in understanding and inform targeted educational interventions. Methods: A cross-sectional survey was conducted among 292 female college students aged 18-25 years at Sri Ramachandra institute of higher education and research. A structured questionnaire evaluated participants' knowledge, perceptions, and awareness of PCOS symptoms, complications, and preventive measures. Data were analyzed using descriptive statistics. Results: While 91.43% of participants had heard of PCOS, only 54.97% correctly identified androgen excess as a key factor. Awareness of symptoms like irregular menstrual cycles 82.19% and hirsutism 66.78% was relatively high, but knowledge of long-term complications such as diabetes 35.27% and heart disease 37.67% was low. Most participants recognized the importance of lifestyle interventions, with 77.05% endorsing regular exercise and 76.36% supporting dietary modifications. Allopathic medicine was the preferred treatment 70.89%, with minimal interest in alternative therapies. Conclusions: The study reveals significant gaps in knowledge regarding the long-term complications of PCOS among college women’s. While awareness of common symptoms is relatively high, targeted educational programs are needed to improve understanding of the syndrome's broader health implications. Healthcare professionals should play a central role in disseminating accurate information to promote early detection and effective management of PCOS.
The COVID-19 pandemic was the cause of the shortage of medicines, the spread of misinformation and the creation of obstacles to the accessibility of the health care system. Therefore, patients got a lot of fake claims about drug interactions, side effects, and availability. For the purposes of addressing these issues, Pharm-AI, an AI-powered chatbot, has been invented to give the patients the right and real-time information about the medicines they need, to help them find the nearest pharmacies, and to clarify any medication-related questions. Pharm-AI uses natural language processing with geolocation mapping to improve healthcare accessibility and decision-making. It uses data from very reliable sources such as PubMed, Scopus, Drug Central, and clinical trials to give evidence-based responses and thus to lower misinformation risks.Some preliminary analyses have demonstrated that Pharm-AI is a very successful tool in the fight against information overload that allows users to get sound drug-related insights very quickly. Its geolocation element provides the data needed to identify the pharmacies where the medicine is available. This results in a 65% decrease in the time needed to locate medications as compared to manual searches. Moreover, Pharm-AI helps people save money especially in the low-income regions by comparing the prices of generic and branded drugs and so, it stimulates the transparency of the costs. One of the weaknesses for example is the platform might have to depend on third party pharmaceutical companies’ inventories and the use of certain languages in regional dialects which are affective limitations. The new solutions will involve using optical character recognition (OCR) for prescription analysis, multilingual support, and affiliating with online pharmacies for automated medication delivery. Pharm-AI is a step forward in the development of AI-driven healthcare solutions, so it is going to make the health care system better and the information about the drugs more reliable.
Vonoprazan is a potassium competitive acid blocker, has shown potential used to treat acid reflux and eliminating Helicobacter pylori. Its enhanced anti-secretory action, quick action, and reduced anti-secretory variability make it a more suitable option than PPIs. However, many research is needed to fully understand the effects and its safety and tolerability profiles. The drug's effectiveness in treating reflux esophagitis is also reviewed. Due to the limits and unfulfilled therapeutic needs of proton pump inhibitors (PPIs), new medications also developed to address acid-related disorders and the elimination of H. pylori. Vonoprazan, a recently developed potassium-competitive acid blocker (P-CAB), demonstrated greater inhibition of stomach acid secretion. The effectiveness of vonoprazan in treating illnesses linked to acid reflux is reviewed in this paper, with an emphasis on its application in the elimination of Helicobacter pylori. Professional judgement: Vonoprazan demonstrated a few benefits over PPIs for the pharmacokinetic and pharmacodynamic characteristics of the drug: more powerful and extended suppression of acid secretion, quick commencement of action without the need for acid activation and precise dosing time, includes reduced anti-secretory variability and improved acid regulation at night. According to recent research, vonoprazan's enhanced anti-secretory action may make it a more suitable option than PPIs for treating reflux esophagitis and eliminating Helicobacter pylori. Furthermore, vonoprazan has good safety and tolerability profiles, albeit more extensive research is needed to fully understand its effects.
The COVID-19 pandemic was the cause of the shortage of medicines, the spread of misinformation and the creation of obstacles to the accessibility of the health care system. Therefore, patients got a lot of fake claims about drug interactions, side effects, and availability. For the purposes of addressing these issues, Pharm-AI, an AI-powered chatbot, has been invented to give the patients the right and real-time information about the medicines they need, to help them find the nearest pharmacies, and to clarify any medication-related questions. Pharm-AI uses natural language processing with geolocation mapping to improve healthcare accessibility and decision-making. It uses data from very reliable sources such as PubMed, Scopus, Drug Central, and clinical trials to give evidence-based responses and thus to lower misinformation risks.Some preliminary analyses have demonstrated that Pharm-AI is a very successful tool in the fight against information overload that allows users to get sound drug-related insights very quickly. Its geolocation element provides the data needed to identify the pharmacies where the medicine is available. This results in a 65% decrease in the time needed to locate medications as compared to manual searches. Moreover, Pharm-AI helps people save money especially in the low-income regions by comparing the prices of generic and branded drugs and so, it stimulates the transparency of the costs. One of the weaknesses for example is the platform might have to depend on third party pharmaceutical companies’ inventories and the use of certain languages in regional dialects which are affective limitations. The new solutions will involve using optical character recognition (OCR) for prescription analysis, multilingual support, and affiliating with online pharmacies for automated medication delivery. Pharm-AI is a step forward in the development of AI-driven healthcare solutions, so it is going to make the health care system better and the information about the drugs more reliable.
PharmVR is an innovative Computer Assisted Learning (CAL) platform designed to transform experimental pharmacology education through immersive Virtual Reality (VR) simulations and AI-driven interactive learning. Developed as an advanced alternative to traditional animal experiments, PharmVR enables pharmacy, medical, and veterinary students to perform realistic, 3D virtual experiments aligned with the curriculum standards of the Pharmacy Council of India (PCI) and National Medical Commission (NMC).The platform integrates gamified learning modules, real-time performance scoring, and an intelligent virtual tutor that adapts to individual learning styles. In a move toward inclusive education, PharmVR supports multilingual access, offering content in major Indian languages to break language barriers across diverse regions. The simulation environment replicates laboratory conditions with high fidelity, allowing students to practice, observe, and understand drug effects on virtual animal models in an ethical, engaging, and risk-free setting.Currently in its developmental stage, PharmVR has secured all necessary intellectual property protections including trademarks and patents, and is registered under India's MSME initiative. By combining advanced technology with educational innovation, PharmVR aims to set a new standard for digital pharmacology education in India and beyond.